Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C82684
http://purl.obolibrary.org/obo/NCIT_C82684
Preferred Name

Tovetumab
Definitions
A humanized monoclonal antibody directed against the platelet-derived growth factor receptor (PDGFR) alpha with potential antineoplastic activity. Tovetumab inhibits activation of the cell-surface tyrosine kinase PDGFR alpha subunit and subsequent triggering of mitogenic signaling pathways, including the JAK/STAT, PI3K/Akt, and MAP kinase pathways. PDGFR alpha acts as a mitogenic signaling receptor for cells of mesenchymal origin and inhibition of receptor activity may inhibit tumor cell proliferation.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

A humanized monoclonal antibody directed against the platelet-derived growth factor receptor (PDGFR) alpha with potential antineoplastic activity. Tovetumab inhibits activation of the cell-surface tyrosine kinase PDGFR alpha subunit and subsequent triggering of mitogenic signaling pathways, including the JAK/STAT, PI3K/Akt, and MAP kinase pathways. PDGFR alpha acts as a mitogenic signaling receptor for cells of mesenchymal origin and inhibition of receptor activity may inhibit tumor cell proliferation.
prefLabel
Tovetumab
label
Tovetumab
PDQ_Closed_Trial_Search_ID
633312
code
C82684
Has_Target
prefixIRI
NCIT:C82684
in_subset
Display_Name
Tovetumab
Preferred_Name
Tovetumab
FDA_UNII_Code
2XY62K75UV
Contributing_Source
CTRP
FDA
Maps_To
Tovetumab
CAS_Registry
1243266-04-7
NCI_Drug_Dictionary_ID
633312
Legacy Concept Name
Anti-PDGFR_Alpha_Monoclonal_Antibody_MEDI-575
type
Is_Value_For_GDC_Property
subClassOf
PDQ_Open_Trial_Search_ID
633312
Semantic_Type
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
UMLS_CUI
C2830210
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display